Chronic Lymphocytic Leukemia
The latest news, research, and perspectives in chronic lymphocytic leukemia (CLL). The most common leukemia subtype among adults, CLL occurs when an acquired mutation causes bone marrow to produce abnormal lymphocytes. As these leukemic cells proliferate, the disorder is associated with lymphadenopathy, splenomegaly, and cytopenias.
Advertisement
Novel multiclonal second site BTK mutations can lead to resistance in patients with pre-existing BTK C481 mutations.
A new mutational signature was present in the Richter’s transformation sample from seven of 18 patients.
The multi-omics study identified six CLL subgroups, five of which were associated with genetic features.
The median OS was four months from the date of Richter's transformation, suggesting prognosis "remains poor."
The U.S. Food and Drug Administration (FDA) has approved zanubrutinib for the treatment of CLL and SLL.
BCL2 inhibitors (eg, venetoclax) have clinical benefits for patients with CLL, but overcoming resistance remains a challenge.
Advertisement
Moxetumomab pasudotox will be discontinued from the market in the US in July 2023.
The European Commission has approved zanubrutinib for the treatment of adults with chronic lymphocytic leukemia.
In this episode, Chadi Nabhan, MD, MBA, FACP, talks with Elizabeth Brem, MD, about CLL highlights from ASH 2022.
Matthew Davids, MD, MMSc, of the Dana-Farber Cancer Institute, shares his hopes for CLL treatment and research in 2023.
In follow-up data from the phase II CAPTIVATE study, ibrutinib plus venetoclax demonstrated a favorable benefit-risk profile.
Zanubrutinib may be “more efficacious and better tolerated” than ibrutinib for patients with relapsed/refractory CLL or ...
SOHO President Jennifer R. Brown, MD, PhD, speaks about the phase III ALPINE study, which compared BTK inhibitors in CLL/SLL.
The CLL2-Give trial determined that obinutuzumab, ibrutinib, and venetoclax is a “potent and promising” treatment for ...
Patients with chronic lymphocytic leukemia (CLL) primarily rely on their physicians for information about their disease.
Jennifer R. Brown, MD, PhD; President of SOHO chats with Chadi Nabhan, MD, on the ALPINE study.
Christine Ryan, MD, discusses research presented at the 2022 American Society of Hematology Annual Meeting.
At Blood Cancers Today, we have compiled the year's top content awards as doled out by the Twitterverse.
A new assay for the quantification of MRD in CLL can detect MRD to 10-5 and below.
A new study suggests small extracellular vesicles secreted by leukemia cells reduce anti-tumor T-cell responses.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Elias Jabbour, MDAssociate Editor | Professor in the Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
670 Madison Ave.
Manalapan, NJ 07726